Insys Therapeutics (NASDAQ: INSY) reported Q2 Adj. EPS of ($0.33), $0.17 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $38 million versus the consensus estimate of $25.91 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.